For example, tumours with NTRK fusion may be treated with a larotrectinib; olaparib treatment targets a mutation in the BRCA1 or BRCA2 gene, and pembrolizumab is approved by FDA only in the cancers with MSI-H (microsatellite instability high) or MMR-D (mismatch repair deficiency). The gene discussed is BRCA1; the disease is neoplasm.